^
    Back
    Association details:
    Biomarker:AKT1 mutation
    Cancer:Colorectal Cancer
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor) +
    Cotellic (cobimetinib) (MEK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ESMO-GI 2020
    Title:

    SO-32 Biomarker analysis of the phase III IMblaze370 trial of atezolizumab plus cobimetinib or atezolizumab monotherapy vs regorafenib in third-line CRC

    Published date:
    07/08/2020
    Excerpt:
    Atezolizumab + cobimetinib showed benefit over regorafenib in patients with certain low prevalence tumor subsets, such as those with a PI3K/Akt mutation or WNT pathway wild-type tumors.
    DOI:
    https://doi.org/10.1016/j.annonc.2020.04.047